Cellectis S.a Stock News

Cellectis S.A. (NASDAQ:CLLS) concluded the trading at $4.40 on Friday, February 25 with a rise of 2.56% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $4.29 and 5Y monthly beta was reading 2.19 with its price kept floating in the range … Cellectis S.A.’S 2.56% Escalation Justifies Another Look Read More »

Cellectis (CLLS) appointed Bing Wang as CFO and member of its executive committee.Prior to joining CLLS, Wang was most recently CEO of Refuge Biotechnologies

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced the appointment of Bing C. Wang, PhD, MBA, as Chief Financial Officer and member of Cellectis’ executive committee.

Arovella Therapeutics Ltd (ASX:ALA) has welcomed Dr Mini Bharathan to the executive team to lead preclinical trials of the newly acquired DKK1 peptide targeting technology and its CAR19-iNKT cell the

(RTTNews) - Cellectis said its licensed partner, Allogene Therapeutics Inc. (ALLO) announced that the U.S. Food and Drug Administration has lifted the clinical hold on its cancer drug trial. Allogene reported that the FDA''s investigations concluded that the chromosomal abnormality was unrelated to TALEN gene editing or Allogene''s manufacturing

Gainers: Accolade ACCD +13%, Inari Medical NARI +10%, Cellectis (CLLS) +6%, Intel INTC +5%, Ulta Beauty (ULTA) +4%. Losers: Patrick Industries (PATK) -40%, Rivian Automotive

Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene''s Manufacturing Process Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (NASDAQ: CLLS ), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (NASDAQ: ALLO ) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials. The FDA had placed a clinical hold on all five of Allogene''s clinical trials on October 7, 2021 following a report of a chromosomal abnormality detected in ALLO-501A CAR+ T-cells from a single patient enrolled in Allogene''s ALPHA2 study. Allogene reported today that the investigations concluded that the chromosomal abnormality was unrelated to TALEN® gene editing or Allogene''s manufacturing process and had no clinical significance.

During the last session, Cellectis S.A. (NASDAQ:CLLS)s traded shares were 0.54 million, with the beta value of the company hitting 2.20. At the end of the trading day, the stocks price was $9.07, reflecting an intraday gain of 9.81% or $0.81. The 52-week high for the CLLS share is $34.71, that puts it down -282.69 How Cellectis S.A. (NASDAQ: CLLS) Could Be A Loss Maker Since It Is Down -66.48% YTD? Read More »

JMP Securities reissued their buy rating on shares of Cellectis (NASDAQ:CLLS) in a report published on Tuesday morning, AnalystRatings.com reports. CLLS has been the subject of a number of other reports. William Blair downgraded shares of Cellectis from an outperform rating to a market perform rating in a report on Monday, November 8th. Jonestrading reaffirmed []

JMP Securities reissued their buy rating on shares of Cellectis (NASDAQ:CLLS) in a report published on Wednesday morning, Analyst Ratings Network reports. The firm currently has a $20.00 price target on the biotechnology companys stock. CLLS has been the subject of several other research reports. William Blair cut shares of Cellectis from an outperform rating [] The post Cellectis (NASDAQ:CLLS) Rating Reiterated by JMP Securities appeared first on ETF Daily News .

NEW YORK, Dec. 11, 2021 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company employing its pioneering TALEN® gene-editing platform to develop innovative therapeutics for the treatment of serious diseases, announced today preliminary results from the BALLI-01 Phase 1 study of UCART22, its allogeneic CAR-T cell therapy candidate targeting CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), and preclinical data on TALGlobin01, its autologous cell therapy product candidate for homozygous SCD patients (HbSS) at the 63 rd Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia.

Millennium Management LLC lifted its position in Cellectis S.A. (NASDAQ:CLLS) by 117.4% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 66,268 shares of the biotechnology companys stock after buying an additional 35,781 shares during the quarter. Millennium Management LLCs holdings in Cellectis were worth $1,025,000 as of its most recent SEC filing. Several []

Cellectis (NASDAQ:CLLS)‘s stock had its “buy” rating reiterated by analysts at JMP Securities in a research note issued to investors on Wednesday, Price Targets.com reports. They presently have a $20.00 price target on the biotechnology company’s stock. JMP Securities’ price objective indicates a potential upside of 129.89% from the company’s previous close. A number of […]

JMP Securities reiterated their buy rating on shares of Cellectis (NASDAQ:CLLS) in a report published on Wednesday, Price Targets.com reports. JMP Securities currently has a $20.00 price target on the biotechnology companys stock. Several other brokerages have also commented on CLLS. Robert W. Baird restated a hold rating and issued a $10.00 price target on []

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.